UniProtKB/Swiss-Prot P43115: Variant p.Asn366Ser

Prostaglandin E2 receptor EP3 subtype
Gene: PTGER3
Feedback?

Variant information Variant position:

366 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Asparagine (N) to Serine (S) at position 366 (N366S, p.Asn366Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (N) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs13306014 [ dbSNP | Ensembl ]

Sequence information Variant position:

366 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

390 The length of the canonical sequence.
Location on the sequence:

YLLLRKILLRKFCQIRYHTN N YASSSTSLPCQCSSTLMWSD The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YLLLRKILLRKFCQIRYHTNN--------Y----------------------ASSSTSLPCQCSSTLMWSD

Mouse                         YLLLRKILLRKFCQIRDHTNY--------------------

Rat                           YLLLRKILLRKFCQIRDHTNY--------------------

Pig                           YLLLRKILLQKFCQAVSQKQR--------EEAATLIF----

Bovine                        YLLLRKILLQKFCQLLKGHSYGLDTEGGTENKDKEMKENLY

Rabbit                        YLLLRKILLRKFCQVIHENN---------EQKDEIQRENRN

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 390	Prostaglandin E2 receptor EP3 subtype
Topological domain	350 – 390	Cytoplasmic
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQFWRPASSGSGCQQIRCLMESCSLTQTGVQWSDFRSLQPSPPPLTAIFASWVQVILLPQPPK. In isoform 12.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQPISLSNEIIQTEAEEFWGN. In isoform EP3-III.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQPISLSNEIIQTEAMRKRRLREQEEFWGN. In isoform EP3-IV.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQPISLSNEIIQTEAMRKRRLREQEMGPDGRCFCHAWRQVPRTWCSSHDREPCSVQLS. In isoform EP3-V.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> EEFWGN. In isoform EP3B.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQPISLSNEIIQTEA. In isoform EP3C.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQEEFWGN. In isoform EP3D.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQLICSLQNSQIQRATAHCGQVQTYRVLNREEMEVLVSSINVYTRISTVKTE. In isoform EP3E.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQPISLSNEIIQTEAMRKRRLREQLICSLRTLRYRGQLHIVGKYKPIVC. In isoform EP3E2.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQAPLLPTPTVIDPSRFCAQPFRWFLDLSFPAMSSSHPQLPLTLASFKLLREPCSVQLS. In isoform EP3F.
Alternative sequence	360 – 390	IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> EMGPDGRCFCHAWRQVPRTWCSSHDREPCSVQLS. In isoform EP3G.

Literature citations
No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.